# VOLUME 29 1988

## SUBJECT INDEX


Acquisition, 143
  response patterning
  scopolamine
  selection delays
Acute administration, 169
  ethanol tolerance
  forebrain regions
  monoamine/metabolite content
  selective breeding
Adenosine analogs, 429
  caffeine
  drug interaction
  monkey
Adenosine antagonists, 433
  caffeine
  therapeutic agents
  xanthines
Adenosine receptors, 533
  anticonvulsant activity
  carbamazepine
  central nervous system
  $N^6$-L-phenylisopropyladenosine
  rabbits
Adjunctive drinking, 295
  drug self-administration
  monkeys, rhesus
  scheduled-induced polydipsia
Adrenalectomy, 451
  endogenous opioids
  $\beta$-endorphin
  stress-induced analgesia
$\beta$-Adrenoceptors, 717
  lordosis
  rats, females
Aerosol inhalation, 93
  cocaine smoking
Alcohol, chronic administration, 489
  hypogonadism
  luteinizing hormone levels
  prolactin levels
  testosterone levels
Alcohol drinking, 479
  angiotensin II
  renin-angiotensin system
  satiety
Alcohol intake, 733
  human studies
  methamphetamine metabolism
  urinary excretion
Alfentanil, 573
  brainstem site localization
  drug interaction
  muscle rigidity
Alpidem, 803
  clinical studies
  human studies, anxious patients
Amiloride, 257
  4-aminopyridine
  lingual epithelium
  transport pathways
Amino acids, 73
  convulsant action
  hyperalgesic action
  intrathecal glycine
  strychnine
4-Aminopyridine, 257
  amiloride
  lingual epithelium
  transport pathways
Amitryptiline, chronic, 681
  animal model of depression
  $^3$H-imipramine binding
  olfactory bulbectomy
  open field
  swimming test
Amnesia, 625
  diazepam
  electroconvulsive shock
  passive avoidance
  piracetam
  scopolamine
Amphetamine
  apomorphine, 239
  behavioral hypersensitivity, 239
  cocaine, 239
  GABAergic mechanisms, 457
  locomotor activity, 517
  muscimol, 457
  picrotoxin, 457
  rotational behavior, 457
  subchronic administration, 239
  ultradian activity rhythms, 517
Analgesia
  buprenorphine, 393
  central nervous system, 163
  cold swim stress, 83, 163
  hypothermia, 83
  jump thresholds, 83
  norepinephrine system, 83
  opioid peptide brain levels, 163
  schedule-controlled behavior, 393
  tail-flick tests, 83
  thermoregulation, 83
  tolerance, 393
  yohimbine, 83
Analgesia, milk-induced, 9
  opioid-mediated behaviors
  stress reduction
Angiotensin II, 479
  alcohol drinking
  renin-angiotensin system
  satiety
Animal model
  drug behavioral reversal, 467
  nigro-striatal dopamine system, 59
  prolactin, 59
  social behavioral deficit, 467
  yawning, 59
Animal model of depression
  amitryptiline, chronic, 681
  endogenous GABA, 275
  forced swimming test, 275
  $^3$H-imipramine binding, 681
  olfactory bulbectomy, 681
  open field, 681
  swimming test, 681
Anorexia, 357
  cyclo(His-Pro)
  food intake
Anticholinergics, 205
  consummatory acts
  drug interaction
  neuroleptics
  operant behaviors
Anticonvulsant activity, 533
  adenosine receptors
  carbamazepine
  central nervous system
  $N^6$-L-phenylisopropyladenosine
  rabbits
Antinociception, 351
  delta antagonists
  ICI 154129
  ICI 174864
  route of administration
Antipsychotic drug exposure, 45
  developmentally disabled
  dyskinesia
  human studies
Anxiety
  anxiolytic drugs, 767, 771
  barbiturates, 631
  behavioral inhibition system, 767
  buspirone, 821
  conflict behavior, 631
  convulsants, 631
  cyclohexylideneethyl-5-barbituric acid, 631
  depression, 819
  $5HT_2$ receptors, 819
  punishment suppression, 771
Anxiolytic drug effects, 771
  anxiety
  punishment suppression
Anxiolytic drugs, 767
  anxiety
  behavioral inhibition system
Apomorphine
  amphetamine, 239
  behavioral differences, 529
  behavioral hypersensitivity, 239
  cocaine, 239
  dose-dependent effects, 343
  ethanol reinforcement, 343
  haloperidol, 343, 529
  schedule-induced polydipsia, 483
  sex differences, 529
  subchronic administration, 239
Apparatus
  radial arm maze, 143
Appetite suppressing drugs, 675
  brown adipose tissue
  fenfluramine
  sympathetic firing rate
Arecoline, 587
  discriminative stimuli
  nicotine
  non-cholinergic mechanism
Arthritis, ankle joint, 461
  drug interactions
  sodium nitrate crystals
Atropine methyl nitrate, 231
  real-feeding/sham-feeding comparisons
  sucrose

# VOLUME 29 1988

## SUBJECT INDEX


Acquisition, 143
  response patterning
  scopolamine
  selection delays
Acute administration, 169
  ethanol tolerance
  forebrain regions
  monoamine/metabolite content
  selective breeding
Adenosine analogs, 429
  caffeine
  drug interaction
  monkey
Adenosine antagonists, 433
  caffeine
  therapeutic agents
  xanthines
Adenosine receptors, 533
  anticonvulsant activity
  carbamazepine
  central nervous system
  $N^6$-L-phenylisopropyladenosine
  rabbits
Adjunctive drinking, 295
  drug self-administration
  monkeys, rhesus
  scheduled-induced polydipsia
Adrenalectomy, 451
  endogenous opioids
  $\beta$-endorphin
  stress-induced analgesia
$\beta$-Adrenoceptors, 717
  lordosis
  rats, females
Aerosol inhalation, 93
  cocaine smoking
Alcohol, chronic administration, 489
  hypogonadism
  luteinizing hormone levels
  prolactin levels
  testosterone levels
Alcohol drinking, 479
  angiotensin II
  renin-angiotensin system
  satiety
Alcohol intake, 733
  human studies
  methamphetamine metabolism
  urinary excretion
Alfentanil, 573
  brainstem site localization
  drug interaction
  muscle rigidity
Alpidem, 803
  clinical studies
  human studies, anxious patients
Amiloride, 257
  4-aminopyridine
  lingual epithelium
  transport pathways
Amino acids, 73
  convulsant action
  hyperalgesic action
  intrathecal glycine
  strychnine
4-Aminopyridine, 257
  amiloride
  lingual epithelium
  transport pathways
Amitryptiline, chronic, 681
  animal model of depression
  $^3$H-imipramine binding
  olfactory bulbectomy
  open field
  swimming test
Amnesia, 625
  diazepam
  electroconvulsive shock
  passive avoidance
  piracetam
  scopolamine
Amphetamine
  apomorphine, 239
  behavioral hypersensitivity, 239
  cocaine, 239
  GABAergic mechanisms, 457
  locomotor activity, 517
  muscimol, 457
  picrotoxin, 457
  rotational behavior, 457
  subchronic administration, 239
  ultradian activity rhythms, 517
Analgesia
  buprenorphine, 393
  central nervous system, 163
  cold swim stress, 83, 163
  hypothermia, 83
  jump thresholds, 83
  norepinephrine system, 83
  opioid peptide brain levels, 163
  schedule-controlled behavior, 393
  tail-flick tests, 83
  thermoregulation, 83
  tolerance, 393
  yohimbine, 83
Analgesia, milk-induced, 9
  opioid-mediated behaviors
  stress reduction
Angiotensin II, 479
  alcohol drinking
  renin-angiotensin system
  satiety
Animal model
  drug behavioral reversal, 467
  nigro-striatal dopamine system, 59
  prolactin, 59
  social behavioral deficit, 467
  yawning, 59
Animal model of depression
  amitryptiline, chronic, 681
  endogenous GABA, 275
  forced swimming test, 275
  $^3$H-imipramine binding, 681
  olfactory bulbectomy, 681
  open field, 681
  swimming test, 681
Anorexia, 357
  cyclo(His-Pro)
  food intake
Anticholinergics, 205
  consummatory acts
  drug interaction
  neuroleptics
  operant behaviors
Anticonvulsant activity, 533
  adenosine receptors
  carbamazepine
  central nervous system
  $N^6$-L-phenylisopropyladenosine
  rabbits
Antinociception, 351
  delta antagonists
  ICI 154129
  ICI 174864
  route of administration
Antipsychotic drug exposure, 45
  developmentally disabled
  dyskinesia
  human studies
Anxiety
  anxiolytic drugs, 767, 771
  barbiturates, 631
  behavioral inhibition system, 767
  buspirone, 821
  conflict behavior, 631
  convulsants, 631
  cyclohexylideneethyl-5-barbituric acid, 631
  depression, 819
  $5HT_2$ receptors, 819
  punishment suppression, 771
Anxiolytic drug effects, 771
  anxiety
  punishment suppression
Anxiolytic drugs, 767
  anxiety
  behavioral inhibition system
Apomorphine
  amphetamine, 239
  behavioral differences, 529
  behavioral hypersensitivity, 239
  cocaine, 239
  dose-dependent effects, 343
  ethanol reinforcement, 343
  haloperidol, 343, 529
  schedule-induced polydipsia, 483
  sex differences, 529
  subchronic administration, 239
Apparatus
  radial arm maze, 143
Appetite suppressing drugs, 675
  brown adipose tissue
  fenfluramine
  sympathetic firing rate
Arecoline, 587
  discriminative stimuli
  nicotine
  non-cholinergic mechanism
Arthritis, ankle joint, 461
  drug interactions
  sodium nitrate crystals
Atropine methyl nitrate, 231
  real-feeding/sham-feeding comparisons
  sucrose

Baclofen, 189
chronic administration
desipramine
drug interaction
functional response
4,5,6,7-tetrahydroisoxazolo (4,5-c) pyridin-3-ol
Barbital, 183
brain monoamines
ethanol
lorazepam
motor impairment
selective breeding
Barbiturates, 631
anxiety
conflict behavior
convulsants
cyclohexylideneethyl-5-barbituric acid, 631
Behavior, fenfluramine-induced, 565
fenfluramine
pyridoxine
serotonin
tryptophan
Behavioral differences, 529
apomorphine
haloperidol
sex differences
Behavioral effects, 411
caffeine
tolerance
Behavioral hypersensitivity, 239
amphetamine
apomorphine
cocaine
subchronic administration
Behavioral inhibition, 125
drug interaction
ketanserin
methamphetamine analog
para-chlorophenylalanine
Behavioral inhibition system, 767
anxiety
anxiolytic
Behavioral interactions, 63
caffeine
drug interaction
fixed interval schedule
nicotine
Behavioral tests, 315
chlordiazepoxide actions
drug interaction
ethanol actions
Ro15-1788 effects
Behavioral thermoregulation, 243
ethanol
goldfish
thermoregulatory set point
tolerance
Behavioral toxicity, 309
cholinesterase inhibition
clonidine
soman
Benzodiazepine receptor agonists, 791
electroencephalographic changes
short-term exposure
Benzodiazepine receptor binding, 471
differential modulation
ethanol
strain differences
stress
Benzodiazepine receptor ligands, 799
sleep pharmacology
Benzodiazepine receptors
brain electrical activity, 785
imidazopyridines, 763
omega receptor subtypes, 763
rabbit/rat comparisons, 785
Benzodiazepines, 753
physical dependence
withdrawal
Binding, 775
preclinical studies
pyrazolopyridine non-benzodiazepine anxiolytics
Blood ethanol levels, 509
cognitive-perceptual tasks
ethanol
human studies, females
self-rated ethanol effects
Body weight, 667
circadian rhythm
dose-dependent effects
drinking
eating
ethanol
wheel-running activity
Brain
amygdala, 613
anterior striatum, 169
basal forebrain, 581
basal ganglia, 595
brainstem, 183, 275
caudate-putamen, 525
cerebellum, 183
cerebral cortex, 681
cortex, 183, 213, 275, 613
dorsal hippocampus, 785
frontal cortex, 169, 183, 275, 595
hippocampus, 613
hypothalamus, 163, 169, 183, 275, 541, 613, 681
limbic forebrain, 183
medulla oblongata, 613
mesolimbic area, 595
neocortex, 785
nucleus accumbens, 169, 175, 275
nucleus locus coeruleus, 1
nucleus raphe pontis, 573
pons, 613
raphe nucleus, 97, 573
red nucleus, 785
striatum, 183, 213, 275, 457, 595
substantia nigra, 595
substantia nigra, pars reticulata, 89
thalamus, 613
ventromedial hypothalamic nucleus, 303
Brain amine metabolism, 115
breakfast
monkeys, vervet
social behavior
Brain electrical activity, 785
benzodiazepine receptors
rabbit/rat comparisons
Brain monoamines, 183
barbital
ethanol
lorazepam
motor impairment
selective breeding
Brain self-stimulation, 209
diprenorphine
fixed-ratio schedule
naloxone
Brain serotonin, 559
dietary pyridoxine
histadine
histamine metabolism
tryptophan
Brain serotonin neurons, 269
MDMA
neurotoxicity
Brainstem site localization, 573
alfentanil
drug interaction
muscle rigidity
Breakfast, 115
brain amine metabolism
monkeys, vervet
social behavior
4-Bromo-2,5-dimethoxyamphetamine, 281
monkeys
operant behavior
variability of effects
Brown adipose tissue
appetite suppressing drugs, 675
chronic alcohol intake, 53
cold acclimation, 53
fenfluramine, 675
GDP-binding, 33
nicotine, 33
oxidative enzymes, 53
sympathetic firing rate, 675
thermogenesis, 33
Buprenorphine, 393
analgesia
schedule-controlled behavior
tolerance
Buspirone
anxiety, 821
central dopaminergic system, 823
complex effects, 823
gepirone, 711
5-hydroxytryptamine$_{1A}$, 711
imipramine, 815
ipsapirone, 711
multiple effects, 823
panic disorder, 815
placebo, 815
receptor-mediated effects, 711

Caffeine
adenosine analogs, 429
adenosine antagonists, 433
behavioral effects, 411
behavioral interactions, 63
drug interaction, 63, 429
fixed interval schedule, 63
human studies, 419
monkey, 429
nicotine, 63
reinforcing properties, 419
therapeutic agents, 433
tolerance, 411
xanthines, 433
Calcium antagonist, 129
gastrointestinal motility
stress ulceration
Calcium channels, 381
dyskinesia
iminodipropionitrile
nifedipine
Cannabinoids, 213

neurochemical development
perinatal exposure
tyrosine hydroxylase activity
Captopril, 547
2-deoxyglucose
enalapril
food intake
injectant pH
Carbamazepine, 533
adenosine receptors
anticonvulsant activity
central nervous system
$N^6$-L-phenylisopropyladenosine
rabbits
Carbon monoxide levels, 23
cigarette smoking
EEG
heart rate
human studies
nicotine delivery
photic driving
visual evoked potentials
Catalepsy
D-1/D-2 receptor blockade, 223
drug interaction, 223
haloperidol, 335
prostaglandin levels, 335
radiation, 335
receptor effects, 223
Caudate-putamen, 525
dyskinesia
3-mercaptopropionic acid
unilateral administration
Central dopaminergic system, 823
buspirone
complex effects
multiple effects
Central nervous system
adenosine receptors, 533
analgesia, 163
anticonvulsant activity, 533
carbamazepine, 533
cold swim stress, 163
opioid peptide brain levels, 163
$N^6$-L-phenylisopropyladenosine, 533
rabbits, 533
Central responses, 217
cholinergic drugs
REM sleep deprivation
CGS 8216, 741
dose-dependent effects
drug comparisons
monkeys
schedule-controlled behavior
Chew rate, 747
human studies, males
nicotine gum
plasma nicotine
subjective effects
Chlordiazepoxide actions, 315
behavioral tests
drug interaction
ethanol actions
Ro15-1788 effects
Cholinergic drugs, 217
central responses
REM sleep deprivation
Cholinergic muscarinic binding, 581
lesions, basal forebrain
passive avoidance retention
Cholinergically-based learning, 325
Morris water task
strain differences
Cholinesterase inhibition, 309
behavioral toxicity
clonidine
soman
Chronic administration
baclofen, 189
cocaine, 755
desipramine, 189
drug interaction, 189
functional response, 189
self-stimulation, 755
4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol, 189
train-duration thresholds, 755
Chronic alcohol intake, 53
brown adipose tissue
cold acclimation
oxidative enzymes
Cigarette smoking, 23
carbon monoxide levels
EEG
heart rate
human studies
nicotine delivery
photic driving
visual evoked potentials
Circadian fluctuations, 595
Met-enkephalin-like immunoreactivity
pain responsiveness
Circadian rhythm, 667
body weight
dose-dependent effects
drinking
eating
ethanol
wheel-running activity
Clinical pharmacology, 797
non-benzodiazepine anxiolytics
Clinical studies
alpidem, 803
general practice, 811
human studies, anxious patients, 803
hypnotic agents, 811
Clonidine
behavioral toxicity, 309
cholinesterase inhibition, 309
human studies, males, 649
marijuana, 649
physiologic effects, 649
soman, 309
subjective effects, 649
Cocaine
amphetamine, 239
apomorphine, 239
behavioral hypersensitivity, 239
chronic administration, 755
self-stimulation, 755
subchronic administration, 239
train duration thresholds, 755
Cocaine effects, 157
heart rate
inbred strains
locomotor activity
Cocaine smoking, 93
aerosol inhalation
Cognitive-perceptual tasks, 509
blood ethanol levels
ethanol
human studies, females
self-rated ethanol effects
Cold acclimation, 53
brown adipose tissue
chronic alcohol intake
oxidative enzymes
Cold water swim stress
analgesia, 83, 163
central nervous system, 163
hypothermia, 83
jump thresholds, 83
norepinephrine system, 83
opioid peptide brain levels, 163
tail-flick tests, 83
thermoregulation, 83
yohimbine, 83
Complex effects, 823
central dopaminergic system
buspirone
multiple effects
Conflict behavior, 631
anxiety
barbiturates
convulsants
cyclohexylideneethyl-5-barbituric acid
Consummatory acts, 205
anticholinergics
drug interaction
neuroleptics
operant behavior
Convulsant action, 73
amino acids
hyperalgesic action
intrathecal glycine
strychnine
Convulsants, 631
anxiety
barbiturates
conflict behavior
cyclohexylideneethyl-5-barbituric acid
Corticosterone, 699
exogenous administration
oxytocin
prolactin
psychological stress
Cross-tolerance, 365
ethanol
nicotine
tolerance
Cyclic Alternating Pattern Rate, 827
homeostasis
sleep organization
white noise
zolpidem
Cyclohexylideneethyl-5-barbituric acid, 631
anxiety
barbiturates
conflict behavior
convulsants
Cyclo(His-Pro), 357
anorexia
food intake
Cyclopyrrolone hypnotic, 831
zopiclone

D-1/D-2 receptor blockade, 223
catalepsy
drug interaction
receptor effects
Decerebration, 725
ethylketazocine
hyperalgesia
nicotine
Delta antagonists, 351

antinociception
ICI 154129
ICI 174864
route of administration
2-Deoxyglucose, 547
captopril
enalapril
food intake
injectant pH
Depression, 819
anxiety
$5HT_2$ receptors
Desensitization, 375
nicotinic receptors
seizures, nicotine induced
Desipramine, 189
baclofen
chronic administration
drug interaction
functional response
4,5,7,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol
Developmentally disabled, 45
antipsychotic drug exposure
dyskinesia
human studies
Diabetes, 495
energy balance
morphine
nalmefene
opioids
Diazepam, 625
amnesia
electroconvulsive shock
passive avoidance
piracetam
scopolamine
Dietary pyridoxine, 559
brain serotonin
histadine
histamine metabolism
tryptophan
Differential modulation, 471
benzodiazepine receptor binding
ethanol
strain differences
stress
Diprenorphine, 209
brain self-stimulation
fixed-ratio schedule
naloxone
Discriminative effects, 201
morphine
reduced body weight
restricted feeding
Discriminative stimuli, 587
arecoline
nicotine
non-cholinergic mechanism
Dose-dependent effects
apomorphine, 343
body weight, 667
CGS 8216, 741
circadian rhythm, 667
drinking, 667
drug comparisons, 741
eating, 667
ethanol, 667
ethanol reinforcement, 343
haloperidol, 343
monkeys, 741
schedule-controlled behavior, 741
wheel-running activity, 667
Dosing procedure, 553
human studies
marijuana smoke
Dopamine receptor agonist, 89
intranigral injections
rotation
8-OH-DPAT, 193
drug discrimination
ipsapirone
stimulus properties
yohimbine
Drinking
body weight, 667
circadian rhythm, 667
dose-dependent effects, 667
ethanol, 39, 667
d-fenfluramine, 687
naloxone, 39
saccharin preference, 687
wheel-running activity, 667
Drinking modification, 331
naloxone
Droperidol, 609
drug interaction
motor coordination
mu receptor agonists
Drug
ACTH (4–10), 635
alanine, 303
alcohol, 489, 733
alfentamil, 573
alpidem, 803
amiflamine, 97
amitryptiline, 681
amphetamine, 239, 249, 287, 457, 517, 645
d-amphetamine, 403
apomorphine, 59, 223, 239, 249, 343, 403, 483, 529
arecoline, 587, 635
atropine, 309
atropine methyl nitrate, 231
baclofen, 189
barbital, 183
bicuculline, 275, 321
bromocriptine, 223, 489
4-bromo-2,5-dimethoxyamphetamine, 281
buprenorphine, 393
buspirone, 711, 815, 821, 823
caffeine, 63, 411, 419, 429
cannabidiol, 213
capsaicin, 461
captopril, 547
carbamazepine, 533
CGS 8216, 741
chlordiazepoxide, 315
m-chlorophenylpiperazine, 467
cimoxatone, 97
CI 218,872, 785, 791
clenbuterol, 467
clomipramine chlorhydrate, 467
clonazepam, 785, 791
clonidine, 287, 309, 635, 649, 741
cocaine, 157, 239, 295, 755
colchicine, 461
"crack", 93
cyclohexylideneethyl-5-barbituric acid, 631
cyclo(His-Pro), 357
(−)-cytisine, 725
DADLE, 387
DAME, 387
4-deoxypyridoxine, 275
desipramine, 189
dexamethasone, 451, 461
diazepam, 295, 467, 625, 741, 753, 785, 791
diethyldithiocarbamate, 287
diprenorphine, 209
dopamine, 483
8-OH-DPAT, 193
droperidol, 609
enalapril, 547
ethanol, 39, 53, 105, 133, 169, 183, 243, 315, 321, 365, 471, 509, 601, 667, 693, 725
5′-N-ethylcarboxamidoadenosine 429
fenfluramine, 675
d-fenfluramine, 687
fenfluramine chlorhydrate, 467
fentanyl, 609
FK-33824, 387
flunitrazepam, 785, 791
fluoxetine, 635
β-funaltrexamine, 351
gepirone, 711
glycine, 303
guanethidine, 461
haloperidol, 205, 335, 343, 529
hexamethonium, 451
8-hydroxy-2-(di-n-propylamino) tetralin, 467
ibotenic acid, 403
ICI 154129, 351
ICI 174864 351
ICI 190,622, 775
iminodipropionitrile, 381
imipramine, 815
imipramine chlorhydrate, 467
indolpine, 467
ipsapirone, 193, 711
isoniazide, 275
ketanserin, 125
lithium chloride, 79
(−)-lobeline, 725
lorazepam, 183
marijuana, 649
MDMA, 645
mecamylamine, 725
3-mercaptopropionic acid, 525
mesulergine, 197
5,methoxy-N-N-dimethyltryptamine, 467
5-methoxy-3 (1,2,3,6-tetrahydro-pyridin-4-yl) 1-H indole, 467
methsuximide, 641
3,4-methylendioxymethamphetamine, 269
methylnaloxonium, 573
alpha-benzyl-N-methylphenethyl-amine, 125
(+)-methylpiperidine, 725
methysergide, 645
metyrapone, 451
moclobemide, 97
molindone, 223
morphine, 175, 201, 387, 397, 461, 495, 609, 617
muscimol, 321, 457
nalmefene, 495
naloxone, 39, 163, 209, 331, 351, 387,

613, 635, 705
naltrexone, 9, 725
nicotine, 33, 63, 365, 375, 587, 661
(−)-nicotine, 725
(+)-nicotine, 725
nifedipine, 381
nitrendipine, 129
para-chlorophenylalanine, 97, 125
pentazocine, 397
pentobarbital, 471
phenoxybenzamine, 287
phenylbutazone, 461
phenylethylamine, 287
$N^6$-L-phenylisopropyladenosine, 533
R-$N^6$-phenylisopropyladenosine, 429
phenylpropanolamine, 79
physostigmine, 59
picrotoxin, 275, 321, 457
pindolol, 197
piracetam, 625
piribedil, 635
progesterone, 303
propranolol, 197
quinpirole, 89
reserpine, 451
Ro15-1788, 315, 741, 753
SCH 23390, 223
scopolamine, 15, 143, 205, 625
serotonin, 387
SKF 38393, 89, 223
sodium nitrate crystals, 461
sodium valproate, 275
soman, 309
streptozotocin, 495
strychnine, 73, 303
sufentanil, 609
taurine, 303
$\Delta^8$-tetrahydrocannabinol, 67, 213
4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol, 189
toloxatone, 97
tripelennamine, 397
1-(3-trifluoromethylphenyl)piperazine, 197, 467
Wy-47,037, 129
yohimbine, 83, 193
zopiclone, 785, 831
zolpidem, 781, 785, 807, 827

Drug behavioral reversal, 467
animal model
social behavioral deficit

Drug comparisons, 741
CGS 8216
dose-dependent effects
monkeys
schedule-controlled behavior

Drug discrimination
drug interactions, 397
ipsapirone, 193
8-OH-DPAT, 193
morphine, 397
pentazocine, 397
pigeons, 397
stimulus properties, 193
tripelennamine, 397
yohimbine, 193

Drug dose, 635
memory enhancement
training-testing interval

Drug interaction
adenosine analogs, 429
alfentanil, 573
centicholinergics, 205
arthritis, ankle joint, 461
baclofen, 189
behavioral inhibition, 125
behavioral interactions, 63
behavioral tests, 315
brainstem site localization, 573
caffeine, 63, 429
catalepsy, 223
chronic administration, 189
chlordiazepoxide actions, 315
consummatory acts, 205
D-1/D-2 receptor blockade, 223
desipramine, 189
droperidol, 609
drug discrimination, 397
ethanol actions, 315
feeding behavior regulation, 387
fixed interval schedule, 63
food deprivation, 387
functional response, 189
ketanserin, 125
methamphetamine analog, 125
monkey, 429
morphine, 387, 397
motor coordination, 609
mu receptor agonists, 609
muscle rigidity, 573
naloxone, 387
neuroleptics, 205
nicotine, 63
operant behaviors, 205
opioids, 387
para-chlorophenylalanine, 125
pentazocine, 397
pigeons, 397
receptor effects, 223
Ro15-1788 effects, 315
route of administration, 387
sodium nitrate crystals, 461
4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol, 189
tripelennamine, 397

Drug self-administration, 295
adjunctive drinking
monkeys, rhesus
scheduled-induced polydipsia

Dyskinesia
antipsychotic drug exposure, 45
calcium channels, 381
caudate-putamen, 525
developmentally disabled, 45
human studies, 45
iminodipropionitrile, 381
3-mercaptopropionic acid, 525
nifedipine, 381
unilateral administration, 525

Eating
body weight, 667
circadian rhythm, 667
dose-dependent effects, 667
ethanol, 667
d-fenfluramine, 687
saccharin preference, 687
wheel-running activity, 667

EEG, 23
carbon monoxide levels
cigarette smoking
heart rate
human studies
nicotine delivery
photic driving
visual evoked potentials

Electroconvulsive shock, 625
amnesia
diazepam
passive avoidance
piracetam
scopolamine

Electroencephalographic changes, 791
benzodiazepine receptor agonists
short-term exposure

Enalapril, 547
captopril
2-deoxyglucose
food intake
injectant pH

Energy balance, 495
diabetes
morphine
nalmefene
opioids

Endocrine response, 1
lesion, neurochemical
neophobia
nucleus locus coeruleus
stress

Endogenous GABA, 275
animal model of depression
forced swimming test

Endogenous opioids, 451
adrenalectomy
$\beta$-endorphin
stress-induced analgesia

$\beta$-Endorphin, 451
adrenalectomy
endogenous opioids
stress-induced analgesia

Met-Enkephalin-like immunoreactivity, 595
circadian fluctuations
pain responsiveness

Estradiol benzoate, 303
lordosis
ovariectomy
strychnine
ventromedial hypothalamic nucleus

Ethanol
barbital, 183
behavioral thermoregulation, 243
benzodiazepine receptor binding, 471
blood ethanol levels, 509
body weight, 667
brain monoamines, 183
circadian rhythm, 667
cognitive-perceptual tasks, 509
cross-tolerance, 365
differential modulation, 471
dose-dependent effects, 667
drinking, 39, 667
eating, 667
GABAergic mechanisms, 321
genetic correlation, 601
goldfish, 243
human studies, females, 509
hyperbaric environment, 133
hyperthermia, 693
hypothermia, 693
lorazepam, 183
memory consolidation, 321
motor impairment, 183
naloxone, 39

nicotine, 365
passive avoidance, 321
pressure reversal, 133
selective breeding, 183
self-rated ethanol effects, 509
spontaneous behavior, 133
strain differences, 471
stress, 471
thermoregulation, 693
thermoregulatory set point, 243
tolerance, 243, 365
voluntary consumption, 601
wheel-running activity, 667
withdrawal, 601
Ethanol actions, 315
behavioral tests
chlordiazepoxide actions
drug interactions
Ro15-1788 effects
Ethanol reinforcement, 343
apomorphine
dose-dependent effects
haloperidol
Ethanol tolerance
acute administration, 169
forebrain regions, 169
monoamine/metabolite content, 169
operant behavior, 105
selective breeding, 169
Ethylketazocine, 725
decerebration
hyperalgesia
nicotine
Exogenous administration, 699
corticosterone
oxytocin
prolactin
psychological stress

Feeding behavior regulation, 387
drug interaction
food deprivation
morphine
naloxone
opioids
route of administration
Feeding/hoarding inhibition, 79
malaise
phenylpropanolamine
Fenfluramine
appetite suppressing drugs, 675
behavior, fenfluramine-induced, 565
brown adipose tissue, 675
pyridoxine, 565
serotonin, 565
sympathetic firing rate, 675
tryptophan, 565
d-Fenfluramine, 687
drinking
eating
saccharin preference
Fixed interval schedule, 63
behavioral interactions
caffeine
drug interaction
nicotine
Fixed ratio schedule, 209
brain self-stimulation
diprenorphine
naloxone
Food deprivation, 387
drug interaction
feeding behavior regulation
morphine
naloxone
opioids
route of administration
Food intake
anorexia, 357
captopril, 547
cyclo(His-Pro), 357
2-deoxyglucose, 547
enalapril, 547
injectant pH, 547
lesions, kainic acid, 175
lesions, nucleus accumbens, 175
morphine, 175
operant behavior, 175
self-administration, 175
water intake, 175
Forced swimming test, 275
animal model of depression
endogenous GABA
Forebrain regions, 169
acute administration
ethanol tolerance
monoamine/metabolite content
selective breeding
Functional response, 189
baclofen
chronic administration
desipramine
drug interaction
4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-ol

$GABA_A$ receptor supramolecular complex, 781
$\omega_1$ recognition sites
zolpidem
GABAergic mechanisms
amphetamine, 457
ethanol, 321
memory consolidation, 321
muscimol, 457
passive avoidance, 321
picrotoxin, 457
rotational behavior, 457
Gastrointestinal motility, 129
calcium antagonist
stress ulceration
GDP-binding, 33
brown adipose tissue
nicotine
thermogenesis
General practice, 811
clinical studies
hypnotic agents
Genetic analysis, 501
seizures, 3-mercaptopropionic acid-induced
strain differences
Genetic correlation, 601
ethanol
voluntary consumption
withdrawal
Gepirone, 711
buspirone
5-hydroxytryptamine$_{1A}$
ipsapirone
receptor-mediated effects
Goldfish, 243
behavioral thermoregulation
ethanol
thermoregulatory set point
tolerance
Gonadectomy, 705
naloxone
opioid mediation
sex differences
swim analgesia

Habituation, 249
motility
stereotypy
stimulant effects
Haloperidol
apomorphine, 343, 529
behavioral differences, 529
catalepsy, 335
dose-dependent effects, 343
ethanol reinforcement, 343
prostaglandin levels, 335
radiation, 335
sex differences, 529
Heart rate
carbon monoxide levels, 23
cigarette smoking, 23
cocaine effects, 157
EEG, 23
human studies, 23
inbred strains, 157
locomotor activity, 157
nicotine delivery, 23
photic driving, 23
visual evoked potential, 23
Histadine, 559
brain serotonin
dietary pyridoxine
histamine metabolism
tryptophan
Histamine metabolism, 559
brain serotonin
dietary pyridoxine
histadine
tryptophan
Homeostasis, 827
Cyclic Alternating Pattern Rate
sleep organization
white noise
zolpidem
Hormone
estradiol benzoate, 303
plasma corticosterone, 151
progesterone, 303
prolactin, 59, 151
thyrotropin releasing hormone, 357
$5HT_2$ receptors, 819
anxiety
depression
Human studies
alcohol intake, 733
antipsychotic drug exposure, 45
caffeine, 419
carbon monoxide levels, 23
cigarette smoking, 23
developmentally disabled, 45
dosing procedure, 553
dyskinesia, 45
EEG, 23
heart rate, 23
marijuana smoke, 553
methamphetamine metabolism, 733

nicotine delivery, 23
photic driving, 23
reinforcing properties, 419
urinary excretion, 733
visual evoked potentials, 23
Human studies, anxious patients, 803
alpidem
clinical studies
Human studies, females, 509
blood ethanol levels
cognitive-perceptual tasks
ethanol
self-rated ethanol effects
Human studies, males
chew rate, 747
clonidine, 649
marijuana, 649
nicotine gum, 747
physiologic effects, 649
plasma nicotine, 747
subjective effects, 649, 747
5-Hydroxytryptamine$_{1A}$, 711
buspirone
gepirone
ipsapirone
receptor-mediated effects
Hyperactivity, 645
locomotor activity
MDMA
methysergide
Hyperalgesia, 725
decerebration
ethylketazocine
nicotine
Hyperalgesic action, 73
amino acids
convulsant action
intrathecal glycine
strychnine
Hyperbaric environment, 133
ethanol
pressure reversal
spontaneous behavior
Hyperthermia, 693
ethanol
hypothermia
thermoregulation
Hypnotic agents, 811
clinical studies
general practice
Hypogonadism, 489
alcohol, chronic administration
luteinizing hormone levels
prolactin levels
testosterone levels
Hypothalamic dynorphin, 541
nocturnal depletion
rats, anorexic, tumor bearing
Hypothermia
analgesia, 83
cold water swims, 83
ethanol, 693
hyperthermia, 693
jump thresholds, 83
norepinephrine system, 83
tail-flick tests, 83
thermoregulation, 83, 693
yohimbine, 83

Ibotenic acid, 403
lesions, striatal
rotational behavior
ICI 154129, 351
antinociception
delta antagonists
ICI 174864
route of administration
ICI 174864, 351
antinociception
delta antagonists
ICI 154129
route of administration
Imidazopyridines, 763
benzodiazepine receptors
omega receptor subtypes
Iminodipropionitrile, 381
calcium channels
dyskinesia
nifedipine
Imipramine, 815
buspirone
panic disorder
placebo
$^3$H-Imipramine binding, 681
amitryptiline, chronic
animal model of depression
olfactory bulbectomy
open field
swimming test
Immobilization stress, 613
naloxone
noradrenaline release
opiate peptide levels
Inbred strains, 157
cocaine effects
heart rate
locomotor activity
Injectant pH, 547
captopril
2-deoxyglucose
enalapril
food intake
Intranigral injections, 89
dopamine receptor agonist
rotation
Intrathecal glycine, 73
amino acids
convulsant action
hyperalgesic action
strychnine
Ipsapirone
buspirone, 711
8-OH-DPAT, 193
drug discrimination, 193
gepirone, 711
5-hydroxytryptamine$_{1A}$, 711
receptor-mediated effects, 711
stimulus properties, 193
yohimbine, 193

Jump thresholds, 83
analgesia
cold water swims
hypothermia
norepinephrine system
tail-flick tests
thermoregulation
yohimbine

Ketanserin, 125
behavioral inhibition
drug interaction
methamphetamine analog
para-chlorophenylalanine

Learning, 15
memory
passive avoidance
scopolamine
Lesions, basal forebrain, 581
cholinergic muscarinic binding
passive avoidance retention
Lesions, kainic acid, 175
food intake
lesions, nucleus accumbens
morphine
operant behavior
self-administration
water intake
Lesions, neurochemical, 1
endocrine response
neophobia
nucleus locus coeruleus
stress
Lesions, nucleus accumbens, 175
food intake
lesions, kainic acid
morphine
operant behavior
self-administration
water intake
Lesions, raphe nucleus, 97
monoamine oxidase inhibitors
mouse killing behavior
serotonin neurotransmission
Lesions, striatal, 403
ibotenic acid
rotational behavior
Lingual epithelium, 257
amiloride
4-aminopyridine
transport pathways
Locomotor activity
amphetamine, 517
cocaine effects, 157
heart rate, 157
hyperactivity, 645
inbred strains, 157
MDMA, 645
methysergide, 645
nicotine, 661
Pavlovian conditioning, 661
ultradian activity rhythms, 517
Lorazepam, 183
barbital
brain monoamines
ethanol
motor impairment
selective breeding
Lordosis
$\beta$-adrenoceptors, 717
estradiol benzoate, 303
ovariectomy, 303
rats, females, 717
strychnine, 303
ventromedial hypothalamic nucleus, 303
Luteinizing hormone levels, 489
alcohol, chronic administration
hypogonadism
prolactin levels
testosterone levels

Malaise, 79
feeding/hoarding inhibition
phenylpropanolamine
Marijuana, 649
clonidine
human studies, males
physiologic effects
subjective effects
Marijuana smoke, 553
dosing procedure
human studies
MDMA
brain serotonin neurons, 269
hyperactivity, 645
locomotor activity, 645
methysergide, 645
neurotoxicity, 269
Memory, 15
learning
passive avoidance
scopolamine
Memory consolidation, 321
ethanol
GABAergic mechanisms
passive avoidance
Memory enhancement, 635
drug dose
training-testing interval
3-Mercaptopropionic acid, 525
caudate-putamen
dyskinesia
unilateral administration
Methamphetamine analog, 125
behavioral inhibition
drug interaction
ketanserin
para-chlorophenylalanine
Methamphetamine metabolism, 733
alcohol intake
human studies
urinary excretion
Method
electroencephalography, 785
gas chromatography, 733
high performance liquid chromatography, 183
marijuana smoke dosing, 553
polysomnography, 807
somnography, 811
Methsuximide, 641
pigeons
schedule-controlled responding
1-(3,4-Methylenedioxyphenyl)-2-aminopropane analogs, 443
stimulus properties
Methysergide, 645
hyperactivity
locomotor activity
MDMA
Monkey
adenosine analogs, 429
4-bromo-2,5-dimethoxyamphetamine, 281
caffeine, 429
CGS 8216, 741
dose-dependent effects, 741
drug comparisons, 741
drug interaction, 429
operant behavior, 281
schedule-controlled behavior, 741
variability of effects, 281
Monkey, rhesus, 295
adjunctive drinking
drug self-administration
scheduled-induced polydipsia
Monkey, vervet, 115
brain amine metabolism
breakfast
social behavior
Monoamine/metabolite content, 169
acute administration
ethanol tolerance
forebrain regions
selective breeding
Monoamine oxidase inhibitors, 97
lesions, raphe nucleus
mouse killing behavior
serotonin neurotransmission
Morphine
diabetes, 495
discriminative effects, 201
drug discrimination, 397
drug interactions, 387, 397
energy balance, 495
feeding behavior regulation, 387
food deprivation, 387
food intake, 175
lesions, kainic acid, 175
lesions, nucleus accumbens, 175
nalmefene, 495
naloxone, 387
operant behavior, 175
opioids, 387, 495
pentazocine, 397
pigeons, 397
reduced body weight, 201
restricted feeding, 201
route of administration, 387
salt intake, 617
salt preference, 617
self-administration, 175
tripelennamine, 397
water intake, 175
Morris water task, 325
cholinergically-based learning
strain differences
Motility, 249
habituation
stereotypy
stimulant effects
Motor coordination, 609
droperidol
drug interaction
mu receptor agonists
Motor impairment, 183
barbital
brain monoamines
ethanol
lorazepam
selective breeding
Mouse killing behavior, 97
lesions, raphe nucleus
monoamine oxidase inhibitors
serotonin neurotransmission
Multiple effects, 823
buspirone
central dopaminergic system
complex effects
Mu receptor agonists, 609
droperidol
drug interaction
motor coordination
Muscimol, 457
amphetamine
GABAergic mechanisms
picrotoxin
rotational behavior
Muscle rigidity, 573
alfentanil
brainstem site localization
drug interaction

Nalmefene, 495
diabetes
energy balance
morphine
opioids
Naloxone
brain self-stimulation, 209
diprenorphine, 209
drinking, 39
drinking modification, 331
drug interaction, 387
ethanol, 39
feeding behavior regulation, 387
fixed-ratio schedule, 209
food deprivation, 387
gonadectomy, 705
immobilization stress, 613
morphine, 387
noradrenaline release, 613
opiate peptide levels, 613
opioid mediation, 705
opioids, 387
route of administration, 387
sex differences, 705
swim analgesia, 705
Neophobia, 1
endocrine response
lesion, neurochemical
nucleus locus coeruleus
stress
Neurochemical development, 213
cannabinoids
perinatal exposure
tyrosine hydroxylase activity
Neuroleptics, 205
anticholinergics
consummatory acts
drug interaction
operant behaviors
Neurotoxicity, 269
brain serotonin neurons
MDMA
Nicotine
arecoline, 587
behavioral interactions, 63
brown adipose tissue, 33
caffeine, 63
cross-tolerance, 365
decerebration, 725
discriminative stimuli, 587
drug interaction, 63
ethanol, 365
ethylketazocine, 725
fixed interval schedule, 63
GDP-binding, 33
hyperalgesia, 725
locomotor activity, 661
non-cholinergic mechanism, 587
Pavlovian conditioning, 661
thermogenesis, 33
tolerance, 365
Nicotine delivery, 23
carbon monoxide levels

cigarette smoking
EEG
heart rate
human studies
photic driving
visual evoked potentials
Nicotine gum, 747
chew rate
human studies, males
plasma nicotine
subjective effects
Nicotinic receptors, 375
desensitization
seizures, nicotine induced
Nifedipine, 381
calcium channels
dyskinesia
iminodipropionitrile
Nigro-striatal dopamine system, 59
animal models
prolactin
yawning
Nocturnal depletion, 541
hypothalamic dynorphin
rats, anorexic, tumor bearing
Non-benzodiazepine anxiolytics, 797
clinical pharmacology
Non-cholinergic mechanism, 587
arecoline
discriminative stimuli
nicotine
Noradrenaline release, 613
immobilization stress
naloxone
opiate peptide levels
Norepinephrine system, 83
analgesia
cold water swims
hypothermia
jump thresholds
thermoregulation
yohimbine
Nucleus locus coeruleus, 1
endocrine response
lesion, neurochemical
neophobia
stress

Olfactory bulbectomy, 681
amitryptiline, chronic
animal model of depression
$^3$H-imipramine binding
open field
swimming test
$\omega_1$ recognition sites, 781
$GABA_A$ receptor supramolecular complex
zolpidem
Omega receptor subtypes, 763
benzodiazepine receptors
imidazopyridines
Open field, 681
amitryptiline, chronic
animal model of depression
$^3$H-imipramine binding
olfactory bulbectomy
swimming test
Operant behavior
anticholinergics, 205
4-bromo-2,5-dimethoxyamphetamine, 281
consummatory acts, 205
drug interaction, 205
ethanol tolerance, 105
food intake, 175
lesions, kainic acid, 175
lesions, nucleus accumbens, 175
monkeys, 281
morphine, 175
neuroleptics, 205
self-administration, 175
variability of effects, 281
water intake, 175
Operant criteria, 67
THC discrimination
sensitivity
Opiate peptide levels, 613
immobilization stress
naloxone
noradrenaline release
Opioid mediation, 705
gonadectomy
naloxone
sex differences
swim analgesia
Opioid-mediated behaviors, 9
analgesia, milk-induced
stress reduction
Opioid peptide brain levels, 163
analgesia
central nervous system
cold swim stress
Opioids
diabetes, 495
drug interaction, 387
energy balance, 495
feeding behavior regulation, 387
food deprivation, 387
morphine, 387, 495
nalmefene, 495
naloxone, 387
route of administration, 387
Ovariectomy, 303
estradiol benzoate
lordosis
strychnine
ventromedial hypothalamic nucleus
Oxidative enzymes, 53
brown adipose tissue
chronic alcohol intake
cold acclimation
Oxytocin, 699
corticosterone
exogenous administration
prolactin
psychological stress

Panic disorder, 815
buspirone
imipramine
placebo
Pain responsiveness, 595
circadian fluctuations
Met-enkephalin-like immunoreactivity
Para-chlorophenylalanine, 125
behavioral inhibition
drug interaction
ketanserin
methamphetamine analog
Passive avoidance
amnesia, 625
diazepam, 625
electroconvulsive shock, 625
ethanol, 321
GABAergic mechanisms, 321
learning, 15
memory, 15
memory consolidation, 321
piracetam, 625
scopolamine, 15, 625
Passive avoidance retention, 581
cholinergic muscarinic binding
lesions, basal forebrain
Pavlovian conditioning, 661
locomotor activity
nicotine
Pentazocine, 397
drug discrimination
drug interactions
morphine
pigeons
tripelennamine
Peptide
angiotensin II, 479
bombesin, 357
oxytocin, 699
Perinatal exposure, 213
cannabinoids
neurochemical development
tyrosine hydroxylase activity
Phenylethylamine, 287
stereotypy
taste aversion
$N^6$-L-Phenylisopropyladenosine, 533
adenosine receptors
anticonvulsant activity
carbamazepine
central nervous system
rabbits
Phenylpropanolamine, 79
feeding/handling inhibition
malaise
Photic driving, 23
carbon monoxide levels
cigarette smoking
EEG
heart rate
human studies
nicotine delivery
visual evoked potentials
Physical dependence, 753
benzodiazepines
withdrawal
Physiologic effects, 649
clonidine
human studies, males
marijuana
subjective effects
Picrotoxin, 457
amphetamine
GABAergic mechanisms
muscimol
rotational behavior
Pigeons
drug discrimination, 397
drug interactions, 397
methsuximide, 641
morphine, 397
pentazocine, 397
schedule-controlled responding, 641
tripelennamine, 397
Piracetam, 625
amnesia
diazepam

electroconvulsive shock
passive avoidance
scopolamine
Pituitary cyclic AMP, 151
plasma corticosterone
prolactin
psychological stress
Placebo, 815
buspirone
imipramine
panic disorder
Plasma corticosterone, 151
pituitary cyclic AMP
prolactin
psychological stress
Plasma nicotine, 747
chew rate
human studies, males
nicotine gum
subjective effects
Polysomnography, 807
sleep apnea syndrome
zolpidem
Preclinical studies, 775
binding
pyrazolopyridine non-benzodiazepine anxiolytics
Pressure reversal, 133
ethanol
hyperbaric environment
spontaneous behavior
Prolactin
animal models, 59
corticosterone, 699
exogenous administration, 699
nigro-striatal dopamine system, 59
oxytocin, 699
pituitary cyclic AMP, 151
plasma corticosterone, 151
psychological stress, 151, 699
yawning, 59
Prolactin levels, 489
alcohol, chronic administration
hypogonadism
luteinizing hormone levels
testosterone levels
Prostaglandin levels, 335
catalepsy
haloperidol
radiation
Psychological stress
corticosterone, 699
exogenous administration, 699
oxytocin, 699
pituitary cyclic AMP, 151
plasma corticosterone, 151
prolactin, 151, 699
Punishment suppression, 771
anxiety
anxiolytic drug effects
Pyrazolopyridine non-benzodiazepine anxiolytics, 775
binding
preclinical studies
Pyridoxine, 565
behavior, fenfluramine-induced
fenfluramine
serotonin
tryptophan

Rabbit, 533
adenosine receptors
anticonvulsant activity
carbamazepine
central nervous system
$N^6$-L-phenylisopropyladenosine
Rabbit/rat comparisons, 785
benzodiazepine receptors
brain electrical activity
Radiation, 335
catalepsy
haloperidol
prostaglandin levels
Rat, anorexic, tumor bearing, 541
hypothalamic dynorphin
nocturnal depletion
Rats, female, 717
$\beta$-adrenoceptors
lordosis
Real-feeding/sham-feeding comparisons, 231
atropine methyl nitrate
sucrose
Receptor effects, 223
catalepsy
D-1/D-2 receptor blockade
drug interaction
Receptor-mediated effects, 711
buspirone
gepirone
5-hydroxytryptamine$_{1A}$
ipsapirone
Reduced body weight, 201
discriminative effects
morphine
restricted feeding
Reinforcing properties, 419
caffeine
human studies
REM sleep deprivation, 217
central responses
cholinergic drugs
Renin-angiotensin system, 479
alcohol drinking
angiotensin II
satiety
Response patterning, 143
acquisition
scopolamine
selection delays
Restricted feeding, 201
discriminative effects
morphine
reduced body weight
Ro15-1788 effects, 315
behavioral tests
chlordiazepoxide actions
drug interaction
ethanol actions
Rotation, 89
dopamine receptor agonist
intranigral injections
Rotational behavior
amphetamine, 457
GABAergic mechanisms, 457
ibotenic acid, 403
lesions, striatal, 403
muscimol, 457
picrotoxin, 457
Route of administration
antinociception, 351
delta antagonists, 351
drug interaction, 387
feeding behavior regulation, 387
food deprivation, 387
ICI 154129, 351
ICI 174864, 351
morphine, 387
naloxone, 387
opioids, 387

Saccharin preference, 687
drinking
eating
d-fenfluramine
Satiety, 479
alcohol drinking
angiotensin II
renin-angiotensin system
Salt intake, 617
morphine
salt preference
Salt preference, 617
morphine
salt intake
Schedule-controlled behavior
analgesia, 393
buprenorphine, 393
CGS 8216, 741
dose-dependent effects, 741
drug comparisons, 741
monkey, 741
tolerance, 393
Schedule-controlled responding, 641
methsuximide
pigeons
Schedule-induced polydipsia
adjunctive drinking, 295
apomorphine, 483
drug self-administration, 295
monkeys, rhesus, 295
Scopolamine
acquisition, 143
amnesia, 625
diazepam, 625
electroconvulsive shock, 625
learning, 15
memory, 15
passive avoidance, 15, 625
piracetam, 625
response patterning, 143
selection delays, 143
Seizures, 3-mercaptopropionic acid-induced, 501
genetic analysis
strain differences
Seizures, nicotine induced, 375
desensitization
nicotinic receptors
Selection delays, 143
acquisition
response patterning
scopolamine
Selective breeding
acute administration, 169
barbital, 183
brain monoamines, 183
ethanol, 183
ethanol tolerance, 169
forebrain regions, 169
lorazepam, 183
monoamine/metabolite content, 169
motor impairment, 183
Self-administration, 175

food intake
lesions, kainic acid
lesions, nucleus accumbens
morphine
operant behavior
water intake
Self-rated ethanol effects, 509
blood ethanol levels
cognitive-perceptual tasks
ethanol
human studies, females
Self-stimulation, 755
chronic administration
cocaine
train-duration thresholds
Sensitivity, 67
THC discrimination
operant criteria
Serotonin, 565
behavior, fenfluramine-induced
fenfluramine
pyridoxine
tryptophan
Serotonin neurotransmission, 97
lesions, raphe nucleus
monoamine oxidase inhibitors
mouse killing behavior
Sex differences
apomorphine, 529
behavioral differences, 529
gonadectomy, 705
haloperidol, 529
naloxone, 705
opioid mediation, 705
swim analgesia, 705
Short-term exposure, 791
benzodiazepine receptor agonists
electroencephalographic changes
Sleep apnea syndrome, 807
polysomnography
zolpidem
Sleep organization, 827
Cyclic Alternating Pattern Rate
homeostasis
white noise
zolpidem
Sleep pharmacology, 799
benzodiazepine receptor ligands
Social behavior, 115
brain amine metabolism
breakfast
monkeys, vervet
Social behavioral deficit, 467
animal model
drug behavioral reversal
Sodium nitrate crystals, 461
arthritis, ankle joint
drug interactions
Soman, 309
behavioral toxicity
cholinesterase inhibition
clonidine
Spontaneous behavior, 133
ethanol
hyperbaric environment
pressure reversal
Stereotypy
habituation, 249
motility, 249
phenylethylamine, 287
stimulant effects, 249
taste aversion, 287
Stimulant effects, 249
habituation
motility
stereotypy
Stimulus antagonism, 197
stimulus generalization
TFMPP stimulus properties
Stimulus generalization, 197
stimulus antagonism
TFMPP stimulus properties
Stimulus properties
8-OH-DPAT, 193
drug discrimination, 193
ipsapirone, 193
1-(3,4-methylenedioxyphenyl-2-amino-propane analogs, 443
yohimbine, 193
Strain differences
benzodiazepine receptor binding, 471
cholinergically-based learning, 325
differential modulation, 471
ethanol, 471
genetic analysis, 501
Morris water task, 325
seizures, 3-mercaptopropionic acid-induced, 501
stress, 471
Stress
benzodiazepine receptor binding, 471
differential modulation, 471
endocrine response, 1
ethanol, 471
lesion, neurochemical, 1
neophobia, 1
nucleus locus coeruleus, 1
strain differences, 471
Stress-induced analgesia, 451
adrenalectomy
endogenous opioids
$\beta$-endorphin
Stress reduction, 9
analgesia, milk-induced
opioid-mediated behaviors
Stress ulceration, 129
calcium antagonist
gastrointestinal motility
Strychnine
amino acids, 73
convulsant action, 73
estradiol benzoate, 303
hyperalgesic action, 73
intrathecal glycine, 73
lordosis, 303
ovariectomy, 303
ventromedial hypothalamic nucleus, 303
Subchronic administration, 239
amphetamine
apomorphine
behavioral hypersensitivity
cocaine
Subjective effects
chew rate, 747
clonidine, 649
human studies, males, 649, 747
marijuana, 649
nicotine gum, 747
physiologic effects, 649
plasma nicotine, 747
Sucrose, 231
atropine methyl nitrate
real-feeding/sham-feeding comparisons
Swim analgesia, 705
gonadectomy
naloxone
opioid mediation
sex differences
Swimming test, 681
amitryptyline, chronic
animal model of depression
$^3$H-imipramine binding
olfactory bulbectomy
open field
Sympathetic firing rate, 675
appetite suppressing drugs
brown adipose tissue
fenfluramine

Tail-flick tests, 83
analgesia
cold water swims
hypothermia
jump thresholds
norepinephrine system
thermoregulation
yohimbine
Taste aversion, 287
phenylethylamine
stereotypy
Testosterone levels, 489
alcohol, chronic administration
hypogonadism
luteinizing hormone levels
prolactin levels
4,5,6,7-Tetrahydroisoxazolo (5-4-c) pyridin-3-ol, 189
baclofen
chronic administration
desipramine
drug interaction
functional response
TFMPP stimulus properties, 197
stimulus antagonism
stimulus generalization
THC discrimination, 67
operant criteria
sensitivity
Therapeutic agents, 433
adenosine antagonists
caffeine
xanthines
Thermogenesis, 33
brown adipose tissue
GDP-binding
nicotine
Thermoregulation
analgesia, 83
cold water swims, 83
ethanol, 693
hyperthermia, 693
hypothermia, 83, 693
jump thresholds, 83
norepinephrine system, 83
tail-flick tests, 83
yohimbine, 83
Thermoregulatory set point, 243
behavioral thermoregulation
ethanol
goldfish
tolerance
Tolerance
analgesia, 393
behavioral effects, 411

behavioral thermoregulation, 243
buprenorphine, 393
caffeine, 411
cross-tolerance, 365
ethanol, 243, 365
goldfish, 243
nicotine, 365
schedule-controlled behavior, 393
thermoregulatory set point, 243
Train-duration thresholds, 755
chronic administration
cocaine
self-stimulation
Training-testing interval, 635
drug dose
memory enhancement
Transport pathways, 257
amiloride
4-aminopyridine
lingual epithelium
Tripelennamine, 397
drug discrimination
drug interactions
morphine
pentazocine
pigeons
Tryptophan
behavior, fenfluramine, 565
brain serotonin, 559
dietary pyridoxine, 559
fenfluramine, 565
histadine, 559
histamine metabolism, 559
pyridoxine, 565
serotonin, 565
Tyrosine hydroxylase activity, 213
cannabinoids
neurochemical development
perinatal exposure

Ultradian activity rhythms, 517
amphetamine
locomotor activity
Unilateral administration, 525
caudate-putamen
dyskinesia
3-mercaptopropionic acid
Urinary excretion, 733
alcohol intake
human studies
methamphetamine metabolism

Variability of effects, 281
4-bromo-2,5-dimethoxyamphetamine
monkeys
operant behavior
Ventromedial hypothalamic nucleus, 303
estradiol benzoate
lordosis
ovariectomy
strychnine
Voluntary consumption, 601
ethanol
genetic correlation
withdrawal
Visual evoked potentials, 23
carbon monoxide levels
cigarette smoking
EEG
heart rate
human studies
nicotine delivery
photic driving

Water intake, 175
food intake
lesions, kainic acid
lesions, nucleus accumbens
morphine
operant behavior
self-administration
Wheel-running activity, 667
body weight
circadian rhythm
dose-dependent effects
drinking
eating
ethanol
Withdrawal
benzodiazepines, 753
ethanol, 601
genetic correlation, 601
physical dependence, 753
voluntary consumption, 601
White noise, 827
Cyclic Alternating Pattern Rate
homeostasis
sleep organization
zolpidem

Xanthines, 433
adenosine antagonists
caffeine
therapeutic agents

Yawning, 59
animal models
nigro-striatal dopamine system
prolactin
Yohimbine
analgesia, 83
cold water swims, 83
8-OH-DPAT, 193
drug discrimination, 193
hypothermia, 83
ipsapirone, 193
jump thresholds, 83
norepinephrine system, 83
stimulus properties, 193
tail flick tests, 83
thermoregulation, 83
Zolpidem
Cyclic Alternating Pattern Rate, 827
$GABA_A$ receptor supramolecular complex, 781
homeostasis, 827
$\omega_1$ recognition sites, 781
sleep apnea syndrome, 807
sleep organization, 827
polysomnography, 807
white noise, 827
Zopiclone, 831
cyclopyrolone hypnotic, 831


## AUTHOR INDEX


Abelson, M. L., 617
Agrasal, C., 489
Akkok, F., 331
Aldrich-Castanik, L., 315
Algeri, S., 823
Allen, J. D., 483
Altman, H. J., 581
Alvarez, W. F., 45
Anelli, S., 827
Arase, K., 675
Arbilla, S., 763
Arcelloni, T., 827
Aronstam, R. S., 309
Asin, K. E., 89
Avril, I., 625

Baldessarini, R. J., 517
Banas, C., 73
Bansinath, M., 609
Barber, N. I., 517
Bare, T. M., 775
Barnhill, J. G., 471
Baron, S. P., 143
Barr, S. I., 667
Bartholini, G., 833
Battaglia, G., 269
Bean, A. J., 357
Bedichek, R. C., 243
Benedetti, M., 533
Beninger, R. J., 249
Benowitz, N. L., 747
Berge, O.-G., 133
Berman, R. F., 581
Berthold, C. W., III, 393
Bertino, M., 617
Beyer, C., 73, 303
Bignami, G., 771
Billington, C. J., 495
Bird, D. C., 105
Blasco, T. A., 573
Blass, E. M., 9
Block, H., 223
Blois, R., 799
Boal, A. S., 115
Bodnar, R. J., 83, 705
Bodor, A. S., 601
Borrell, J., 39
Borsini, F., 189, 275
Bowden, C. R., 357
Bowers, A., 93
Bray, G. A., 33, 675
Brown, D. M., 495
Brun, J. P., 831
Bryant, H. U., 541
Buccafusco, J. J., 15, 309
Bunnell, B. N., 151
Burch, J. B., 365
Burkhardt, C. A., 617

Cadet, J. L., 125, 381
Carlini, E. A., 217
Carr, L. A., 213
Castellano, C., 321
Chait, L. D., 553
Chan, A. W. K., 315
Cherkin, A., 635
Chermat, R., 625
Ciesielski, L., 97
Cirignotta, F., 807
Clark, C. R., 125
Cline, E. J., 573
Coderre, T. J., 461

Collins, A. C., 157, 365, 375
Commissaris, R. L., 631
Cone, E. J., 649
Coppinger, R., 115
Corwin, R. L., 553
Crabbe, J. C., 243, 601
Crawshaw, L. I., 243
Crosland, R. D., 581
Czirr, S. A., 331

Dalton, T. K., 335
D'Aranno, V., 275
Deakin, J. F. W., 819
de Fiebre, C. M., 365
Delaney, D., 641
Del Rio, J., 387
De Luigi, A., 823
De Maio, D., 821
De Medici, D., 785
De Robertis, E., 681
De Simoni, M. G., 823
De Souza, E. B., 269
Di Nicolantonio, R., 547
Dworkin, S. I., 175
Dykstra, L. A., 397

Elrod, K., 15
Ervin, F. R., 115
Esquifino, A. I., 489
Evangelista, S., 275

Fahn, S., 125
Farolfi, A., 807, 827
Fermoso, J., 489
Fernandez-Tome, M. P., 387
Finn, I. B., 411
Fioriti, G., 827
Fisher, H., 559, 565
Fisher, J. S., 609
Fitzgerald, E., 9
Fletcher, P. J., 687
Flood, J. F., 635
Francès, H., 467
Frank, R. A., 755
Freed, W. J., 381

Garcia-Cabrera, I., 133
Gaillard, J.-M., 799
Gatto, G. J., 169
Gerardi, R., 807
Gesellchen, P. D., 351
Giles, R. E., 775
Giuliani, S., 189
Glennon, R. A., 197, 443
Gobaille, S., 97
Goeders, N. E., 175
Gold, L. H., 645
Goldberg, M. E., 775
Goldberg, S. R., 429
Golding, J. F., 23
Gomora, P., 73
Gonzalez, Y., 387
Gordon, C. J., 693
Gorzalka, B. B., 717
Gosnell, B. A., 495
Grace, M., 495
Graefe, J. F., 93
Graham, J. H., 309
Grant, K. A., 295
Gray, J. A., 767
Greenblatt, D. J., 471
Greenwald, N. E., 509
Griffiths, R. R., 419
Grupp, L. A., 479
Guaza, C., 39
Gudelsky, G. A., 711
Guerin, G. F., 175

Hakan, R. L., 661
Hellevuo, K., 183
Henningfield, J. E., 747
Holloway, J. A., 105
Holloway, F. A., 105
Holtzman, S. G., 411
Hunt, W. A., 335
Huttunen, P., 53

Ida, Y., 613
Imeri, L., 823
Isel, F., 97

Jarvis, M. F., 433
Jenden, D. J., 581
Johanson, C. E., 295, 553
Joseph, J. A., 335

Kafetzopoulos, E., 403, 457
Kandasamy, S. B., 335
Kant, G. J., 151
Karkanias, C. D., 357
Katz, J. L., 429
Kempf, E., 1
Kepler, K. L., 83, 705
Kiianmaa, K., 183
Killian, M., 479
Klemm, W. R., 223
Koenig, J. I., 711
Komisaruk, B. R., 73, 103
Konitsiotis, S., 403
Koob, G. F., 573, 645
Kortelainen, M.-L., 53
Kosobud, A., 601
Krahn, D. D., 495
Ksir, C. J., 661
Kumar, M. S. A., 451
Kumar, S., 725
Kuramaji, A., 595
Kutscher, C. L., 287

Lader, M., 797
Lajtha, A., 525
Langan, M. C., 315
Lange, W. R., 649
Langer, S. Z., 763
Laping, N. J., 59
Leander, J. D., 351
Lee, N. S., 559, 565
Lenègre, A., 625
Leong, F. W., 315
Levine, A. S., 495
Levy, A., 79
Lex, B. W., 509
Li, T.-K., 169
Lloyd, K. G., 781
Ljungberg, T., 205
Longo, V. G., 761, 785
Lugaresi, E., 807
Lukas, S. E., 509
Lumeng, L., 169
Lupien, J. R., 33

McBride, W. J., 169
McCloskey, T. C., 631
McKearney, J. W., 281
McKenney, J. D., 197
Magar, K., 93
Malick, J. B., 753, 775
Malven, P. V., 541
Mancinelli, A., 275
Mandel, P., 97
Manha, N. A., 331
Marconi, M., 823
Marglin, S. H., 617
Marks, M. J., 365
Marley, R. J., 501
Martin, B. J., 501
Martin, I., 489
Martin, W. R., 725
Martz, S., 755
Massotti, M., 785, 791
Mateos, A., 489
May, J. E., 45
Mazurski, E. J., 249
Means, L. W., 67
Meiners, B. A., 775
Meli, A., 189, 275
Meltzer, H. Y., 711
Meltzer, L. T., 587
Mendelsohn, L. G., 351
Mendelson, S. D., 717
Meyerhoff, J. L., 151
Michael, R. P., 209
Michaelis, R. C., 105
Miczek, K. A., 451
Miller, L. G., 471
Miner, L. L., 375, 501
Moerschbaecher, J. M., 393
Mokler, D. J., 67
Molina, V., 97
Mondini, S., 807
Montana, W. E., 89
Morley, J. E., 495
Mormede, P, 1
Morselli, P. L., 803
Muhs, G., 559
Muir, J. L., 699
Murphy, J. M., 169
Musch, B., 803

Nava, S., 823
Nemeth-Coslett, R., 747
Neuman, R., 617
Nielsen, S. T., 129
Nissenbaum, J. W., 231
Noda, K., 451

O'Connor, C. S., 243
Ohi, K., 595
Oliveto, A. H., 397
O'Neal, M. F., 67

Parrino, L., 827
Patel, J. B., 753, 775
Patrick, G., 443
Pavone, F., 321
Peele, D. B., 143
Pellettiere, V., 641
Penetrante, M. L., 315
Perego, C., 823
Perlanski, E., 479
Pfeffer, A. O., 343
Pfister, H. P., 699
Pierson, M. E., 197
Poling, A., 641
Pommering, T., 755
Popoli, P., 533
Porsolt, R. D., 625
Porter, J. H., 67
Prada, J. A., 429
Priore, P., 803
Puig, M. M., 609

Raj, A. B., 815
Ramirez, V. D., 59
Reid, L. D., 331, 617
Reynolds, R. D., 559
Richard, C. W., III, 163
Riffee, W. H., 239
Rinarelli, C. A., 753
Robb, R., 257
Robinson, N., 747
Romero, M.-T., 705
Rosecrans, J. A., 67, 587
Roudebush, R. L., 169
Ruth, J. A., 157

Sacchetti, G., 823
Sakaguchi, T., 675
Salama, A. I., 775
Samson, H. H., 343
Sandi, C., 39
Sandoval, Y., 303
Santos, R., 217
Schaefer, G. J., 209
Schanley, D. L., 315
Schiffman, S. S., 257
Schlinger, H., 641
Sclafani, A., 231
Scotti de Carolis, A., 533
Serra, J., 681
Shader, R. I., 471
Shaywitz, B. A., 517
Sheehan, D. V., 815
Sheehan, K. H., 815
Shimosato, K., 733
Shuster, L., 451
Simon, S. A., 257
Slater, J. P., 509
Slifer, B. L., 397
Sloan, J. W., 725
Smith, G. E., 635
Smith, J. E., 175
Smith, N. T., 573
Snodgrass, S. H., 483
Snyder, C. A., 93
Soto, S., 815
Spaggiari, M. C., 827
Spealman, R. D., 741
Stead, A. G., 693
Steele, T. D., 541
Steru, L., 625
Stevens, S., 335
Stewart, R. B., 479
Stockert, M., 681
Stone, R. K., 45
Sulkowski, T. S., 129
Sutherland, M., 115

Takahashi, K., 595
Takashima, M., 595
Tanaka, M., 613
Tang, C. K., 609
Taylor, E., 381
Teicher, M. H., 517
Tejwani, G. P., 163
Terzano, M. G., 827
Thompson, M. L., 451
Toth, E., 525

Trout, J. R., 565
Tsuda, A., 613
Turndorf, H., 609

Ukai, M., 201
Ullman, E. A., 157
Upchurch, M., 325
U'Prichard, D. C., 775

Valerio, A., 785, 791
Van De Poll, N. E., 529
Van Haaren, F., 529
Van Hest, A., 529
Vasas, R. J., 631
Vaswani, K. K., 163
Velley, L., 1
Vlaha, V., 403

Wagner, G. C., 559, 565
Wall, P. D., 461
Walters, D. E., 213
Wanek, E., 239
Wehner, J. M., 325, 501
Weinger, M. B., 573
Weisinger, R. S., 547
Welch, P., 649
Wellman, P. J., 79
Wettstein, J. G., 741
Wheatley, D., 811
White, J. M., 63
Wilcox, R. E., 239
Williams, M., 433
Winter, J. C., 193
Wood, R. W., 93
Woodson, P. P., 419

Yeh, S. Y., 269
Yim, G. K. W., 541
Young, S. N., 115
Yousif, M., 443

Zivkovic, B., 781
Zucconi, M., 807